Impaired apoptosis plays a central role in cancer development and limits the efficacy of
conventional cytotoxic therapies. Deepening understanding of how opposing factions of the …

The ability of a cell to undergo mitochondrial apoptosis is governed by pro-and anti-
apoptotic members of the BCL-2 protein family. The equilibrium of pro-versus anti-apoptotic …

Deregulation of the BCL-2 family interaction network ensures cancer resistance to apoptosis
and is a major challenge to current treatments. Cancer cells commonly evade apoptosis …

We present a phase II, single-arm study evaluating 800 mg daily venetoclax, a highly
selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor in patients with …

Senescent cells, formed in response to physiological and oncogenic stresses, facilitate
protection from tumourigenesis and aid in tissue repair. However, accumulation of such cells …

Defects in apoptotic cell death can promote cancer and impair responses of malignant cells
to anti-cancer therapy. Pro-survival BCL-2 proteins prevent apoptosis by keeping the cell …

The BCL-2 protein family determines the commitment of cells to apoptosis, an ancient cell
suicide programme that is essential for development, tissue homeostasis and immunity. Too …

Apoptotic cell death inhibits oncogenesis at multiple stages, ranging from transformation to
metastasis. Consequently, in order for cancer to develop and progress, apoptosis must be …

B-cell lymphoma 2 (BCL-2) family proteins primarily work as a programmed cell death
regulator, whereby multiple interactions between them determine cell survival. This explains …

The senescence programme is implicated in diverse biological processes, including
embryogenesis, tissue regeneration and repair, tumorigenesis, and ageing. Although in vivo …